SIRT1/2/3 inhibitors (Sirtris)

N/A

Report date: 2025/03/20 09:22:54
NME

Base Information

Drug NameSIRT1/2/3 inhibitors (Sirtris)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNAD-dependent protein deacetylase sirtuin-2 inhibitorsNAD-dependent protein deacetylase sirtuin-3, mitochondrial inhibitorsNAD-dependent deacetylase sirtuin 1 inhibitors
TargetsNAD-dependent protein deacetylase sirtuin-2NAD-dependent deacetylase sirtuin 1NAD-dependent protein deacetylase sirtuin-3, mitochondrial
Therapy Area/IndicationsNerve DegenerationInflammationMetabolic Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSirtris Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSirtris Pharmaceuticals IncGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsNerve DegenerationInflammationMetabolic Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksN/A